ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme

Abstract EN

Background.

Researches on immunotherapy of glioblastoma multiforme (GBM, WHO grade IV) have increased exponentially in recent years.

As a targeted therapy, a series of biomarkers have been identified in local tumor tissue, while circulating marker which could be detected in the body fluids is still lacking.

ADAMTSL4, a secreted glycoprotein, was earlier found to play a critical role in a prognostic signature for primary GBM (pGBM).

We aimed to investigate the role of ADAMTSL4 at transcriptome level and its relationship with clinical practice in pGBM.

Methods.

A cohort of 88 pGBM patients with RNA-seq data from the Chinese Glioma Genome Atlas (CGGA) was analyzed, and 168 pGBM patients from TCGA were included as validation.

Several bioinformatic methods and predictive tools were applied to investigate the ADAMTSL4-associated immune microenvironment status.

Results.

We found that ADAMTSL4 was enriched in GBM (WHO grade IV), especially for those with IDH1/2 wild-type and MGMT unmethylated groups.

According to the TCGA classification scheme, ADAMTSL4 can act as a potential marker for subtypes with poorer prognosis.

Bioinformatic analyses revealed that ADAMTSL4 was significantly correlated to the immune-related processes in GBM (WHO grade IV), especially representing the infiltration of immune cells and complicated tumor microenvironment.

Clinically, high expression of ADAMTSL4 was an independent indicator for poor prognosis.

Conclusion.

The expression of ADAMTSL4 is closely related to the clinicopathologic characteristics of pGBM.

Meanwhile, it may play a critical role in immune-related processes.

As a secreted glycoprotein, ADAMTSL4 is a promising circulating biomarker for pGBM, deserving further investigations.